GSK’s <em>Breo Ellipta</em> Approved With COPD Airflow Obstruction, Exacerbation Claims

GSK’s Breo Ellipta Approved With COPD Airflow Obstruction, Exacerbation Claims

10 May 2013

Once-daily dosing provides a convenience advantage over the other inhaled corticosteroid/long-acting beta-agonist combination products on the COPD market: GlaxoSmithKline’s own Advair and AstraZeneca’s Symbicort.

FDA’s May 10 approval of GlaxoSmithKline PLC’s Breo Ellipta in chronic obstructive pulmonary disease gives the company a successor to its blockbuster respiratory drug Advair with a more convenient dosing regimen.

Breo Ellipta, which combines the inhaled corticosteroid fluticasone furoate with the long-acting beta-agonist vilanterol, is indicated for long-term, once-daily, maintenance...